Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA
August 10, 2023 11:08 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its...
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer
August 01, 2023 07:30 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular...
Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform
July 20, 2022 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular...
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
January 27, 2021 08:00 ET
|
Auron Therapeutics Inc.
WELLESLEY, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced...